Biora Therapeutics Statistics
Total Valuation
Biora Therapeutics has a market cap or net worth of 856,969. The enterprise value is 38.06 million.
| Market Cap | 856,969 |
| Enterprise Value | 38.06M |
Important Dates
The next estimated earnings date is Thursday, March 27, 2025.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biora Therapeutics has 4.42 million shares outstanding. The number of shares has increased by 159.11% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.42M |
| Shares Change (YoY) | +159.11% |
| Shares Change (QoQ) | -50.78% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 4.45% |
| Float | 3.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.65 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.21 |
| EV / Sales | 42.67 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.82 |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.87 |
| Interest Coverage | -8.31 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -154.63% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 15,379 |
| Profits Per Employee | -543,776 |
| Employee Count | 58 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.35% in the last 52 weeks. The beta is 1.34, so Biora Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | -98.35% |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 5.50 |
| Relative Strength Index (RSI) | 18.83 |
| Average Volume (20 Days) | 202,320 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.02 |
Income Statement
In the last 12 months, Biora Therapeutics had revenue of 892,000 and -31.54 million in losses. Loss per share was -10.46.
| Revenue | 892,000 |
| Gross Profit | 892,000 |
| Operating Income | -60.87M |
| Pretax Income | -35.73M |
| Net Income | -31.54M |
| EBITDA | -60.43M |
| EBIT | -60.87M |
| Loss Per Share | -10.46 |
Balance Sheet
The company has 3.20 million in cash and 40.40 million in debt, giving a net cash position of -37.20 million or -8.41 per share.
| Cash & Cash Equivalents | 3.20M |
| Total Debt | 40.40M |
| Net Cash | -37.20M |
| Net Cash Per Share | -8.41 |
| Equity (Book Value) | -106.63M |
| Book Value Per Share | -28.99 |
| Working Capital | -114.56M |
Cash Flow
In the last 12 months, operating cash flow was -45.92 million and capital expenditures -280,000, giving a free cash flow of -46.20 million.
| Operating Cash Flow | -45.92M |
| Capital Expenditures | -280,000 |
| Free Cash Flow | -46.20M |
| FCF Per Share | -10.45 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -6,824.33% |
| Pretax Margin | -4,005.83% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biora Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -159.11% |
| Shareholder Yield | -159.11% |
| Earnings Yield | -5,399.54% |
| FCF Yield | -5,391.44% |
Stock Splits
The last stock split was on Invalid Date. It was a reverse split with a ratio of 0.1.
| Last Split Date | Invalid Date |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Biora Therapeutics has an Altman Z-Score of -116.46. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -116.46 |
| Piotroski F-Score | n/a |